skip to Main Content
Patented (and Unapproved) Therapeutic Uses For CBD Cannabis Patent Review II

There are plenty of reports and testimonials on the medical benefits of cannabis. Time, and better data, will determine whether these benefits are realized, and whether some are overblown, and the U.S. FDA will decide when the therapeutic uses of cannabinoids are safe and effective, and approvable for human use in the U.S. The FDA has approved CBD (cannabidiol), the principal non-psychoactive constituent in cannabis, for the treatment of certain types of seizures. The approval of Epidiolex (NDA Approval Holder: GW Research Ltd.) brings the therapeutic use of CBD as an active drug substance within the jurisdiction of the FDA. Thus, because CBD is the active drug substance in an FDA-approved pharmaceutical (Epidiolex), the FDA is currently considering regulations for the testing and approval for all drug products containing CBD. See, https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process.

While the FDA is considering how best to handle the testing and approval of therapeutic CBD products, the U.S. Patent and Trademark Office (PTO) is granting patents on unapproved medical uses for CBD and other cannabinoids. The PTO has granted many patents for uses of CBD as a therapeutic in humans and pets, and dozens more are pending. This article is a survey of some patented (and unapproved) uses for CBD since the end of 2018, and the data presented in those patents to support the claims to the medical use of CBD. I highlight some trends and offer my observations for those in the field navigating this new and growing landscape of U.S. patents, and for those considering whether their own innovations into new uses for CBD, or other cannabinoids, might be patentable.  [Read More @ linkedin]

In Case You Missed It

2019 Cannabis Patent Review I: Extraction and Purification

 

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Marijuana industry reps try to sell state lawmakers on process to help reduce testing costs in Oklahoma

Cannabis industry representatives told Oklahoma lawmakers during an interim study Monday that adopting standard practices used by food and drug makers could make medical marijuana cheaper and safer. They tried to sell lawmakers on process validation, a system where data is collected at different stages of manufacturing to ensure safety. Apothecary Farms and Apothecary Extracts…

Wait a Minute Mr. Postman: USPS Nixes Cannabis and Hemp ENDS in the Mail

by Hilary Bricken, Principal, Harris Bricken Back in 2015, we wrote about the U.S. Postal Service (“USPS”) taking issue with companies placing cannabis ads in the mail. In a written notice dated November 27, 2015, issued by the Portland, Oregon, District Mailing Requirements Office, the USPS  explained: [i]f a mailpiece contains an advertisement for marijuana,…

Montana regulators preparing rules ahead of recreational marijuana launch

The first day of adult-use marijuana sales in Montana will be Jan. 1, 2022. Montana Department of Revenue leaders say they’re confident that they’ll be ready for that important date, but there’s a lot of work to do over the next two months. “The deadlines are aggressive,” said Kristan Barbour, administrator of the department’s Cannabis…

New York Cannabis Board Calls Free Marijuana Samples Illegal

The head of the state’s Cannabis Control Board has declared businesses giving away marijuana as a promotion with the purchase of an overpriced T-shirt, lighter or other item are breaking the law. Tremaine Wright, the former state Assembly member who chairs the regulatory body for New York’s newborn marijuana industry, addressed the increasingly common practice…

More Categories

Back To Top
×Close search
Search